Semaglutide Weight Management and Cardiovascular Risk Reduction

Change in body weight (%) Oral semaglutide 25 and 50 mg demonstrated statistically significant higher weight loss vs 14 mg in the PIONEER plus trial Higher body weight reduction with oral semaglutide 25 mg and 50 mg compared to 14 mg Mean baseline body weight: 96.4kg 0.0 -2.0 -4.0 -6.0 -8.0 -10.0 04 8 12 16 20 26 32 Time since randomisation (weeks) Oral sema 14 mg Oral sema 25 mg -4.5% -7.0% % of patients 100 75 Categorical weight loss after 52 weeks of treatment 50 44.1% 25 75.7% 63.2% 43.9% 32.4% 15.7% 0 -9.2% Oral sema Oral sema Oral sema Oral sema 38 44 52 52* 14 mg 25 mg 50 mg 14 mg Oral sema 25 mg Oral sema ≥5% body weight reduction 50 mg ≥10% body weight reduction Oral sema 50 mg Note: Observed data are on-treatment. Week 52* is the body weight change using the trial product estimand. Sema: Semaglutide

View entire presentation